Osimertinib
- PDF / 169,033 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 46 Downloads / 157 Views
1 S
Radiation pneumonitis: 2 case reports In a study of 11 patients treated for lung adenocarcinoma harbouring EGFR T790M at an institute between January 2017 and December 2019, 2 patients [ages and sexes not stated] were described, who developed grade II radiation pneumonitis (RP; n=1) and fatal RP (n=1) during treatment with oral osimertinib 80 mg/d for lung adenocarcinoma [durations of treatments to reactions onsets not stated]. Concurrently, they received thoracic radiotherapy. It was noted that osimertinib increased the risk of RP along with radiotherapy [not all outcomes stated]. Jia W, et al. Osimertinib Greatly Increase the Risk of Radiotherapy Pneumonitis when Concurrent with Thoracic Radiotherapy. International Journal of Radiation Oncology, 803505931 Biology, Physics : Nov 2020. Available from: URL: https://www.sciencedirect.com/journal/international-journal-of-radiation-oncology-biology-physics [abstract]
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
